La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Knight Therapeutics Bilan de santé

Santé financière contrôle des critères 5/6

Knight Therapeutics possède un total de capitaux propres de CA$762.8M et une dette totale de CA$51.0M, ce qui porte son ratio d'endettement à 6.7%. Son actif total et son passif total sont CA$945.4M et de CA$182.6M. L'EBIT de Knight Therapeutics est CA$8.0M ce qui fait que son ratio de couverture des intérêts 41.5. Elle dispose de liquidités et de placements à court terme de CA$157.5M.

Informations clés

6.7%

Ratio d'endettement

CA$50.95m

Dette

Ratio de couverture des intérêts	41.5x
Argent liquide	CA$157.47m
Fonds propres	CA$762.80m
Total du passif	CA$182.56m
Total des actifs	CA$945.36m

Mises à jour récentes de la santé financière

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03

Recent updates

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28

Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

May 07

Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Apr 07

Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

Mar 20

If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Mar 02

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03

Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

Jan 19

What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

Jan 04

A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Dec 20

The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

Dec 07

What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 02

Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021

Nov 17

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de GUD ( CA$360.6M ) dépassent ses passifs à court terme ( CA$105.8M ).

Passif à long terme: Les actifs à court terme de GUD ( CA$360.6M ) dépassent ses passifs à long terme ( CA$76.7M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: GUD dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de GUD est passé de 0% à 6.7% au cours des 5 dernières années.

Couverture de la dette: La dette de GUD est bien couverte par le flux de trésorerie opérationnel ( 123.5% ).

Couverture des intérêts: Les paiements d'intérêts de GUD sur sa dette sont bien couverts par l'EBIT ( 41.5 x couverture).

Knight Therapeutics Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Recent updates

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Knight Therapeutics Inc. Revises Earnings Guidance for the Year 2024

Knight Therapeutics Inc. to Report Q2, 2024 Results on Aug 08, 2024

Independent Director recently sold CA$148k worth of stock

Executive Chairman exercised options to buy CA$543k worth of stock.

Price target increased by 7.3% to CA$7.24

Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024

First quarter 2024 earnings released: CA$0.045 loss per share (vs CA$0.035 loss in 1Q 2023)

Knight Therapeutics Inc. to Report Q1, 2024 Results on May 09, 2024

President exercised options to buy CA$309k worth of stock.

Full year 2023 earnings released: CA$0.16 loss per share (vs CA$0.26 loss in FY 2022)

Knight Therapeutics Inc. to Report Q4, 2023 Results on Mar 21, 2024

Knight Therapeutics Inc., Annual General Meeting, May 08, 2024

Knight Therapeutics Inc. Announces Regulatory Submission of Fostamatinib in Brazil

Knight Therapeutics Inc. Announces Launch of Bijuva® in Canada

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Knight Therapeutics Inc. to Report Q3, 2023 Results on Nov 09, 2023

Knight Therapeutics Inc. Announces CMED Price Approval of Minjuvi (tafasitamab) in Brazil

United Medical Ltd. Announces Regulatory Submission of Pemigatinib in Brazil

Executive Chairman recently bought CA$111k worth of stock

Knight Therapeutics Inc. Updates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Knight Therapeutics Inc. to Report Q2, 2023 Results on Aug 10, 2023

Insufficient new directors

President recently bought CA$95k worth of stock

Knight Therapeutics Inc. Updates Revenue Guidance for the Fiscal 2023

First quarter 2023 earnings released: CA$0.035 loss per share (vs CA$0.16 loss in 1Q 2022)

Knight Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 309%

Price target decreased by 12% to CA$6.30

Knight Therapeutics Inc. Announces Relaunch of AKYNZEO in Canada

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Knight Therapeutics Inc. Reports Impairment of Intangible Assets for the Third Quarter Ended September 30, 2022

Knight Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022

Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Knight Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022

Executive Chairman recently bought CA$135k worth of stock

Executive Chairman recently bought CA$104k worth of stock

Executive Chairman recently bought CA$207k worth of stock

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2022

Knight Therapeutics Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to CA$6.86

Independent Director recently bought CA$89k worth of stock

President recently bought CA$104k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

Knight Therapeutics Inc., Annual General Meeting, May 11, 2022

Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia

Executive Chairman recently bought CA$102k worth of stock

Executive Chairman recently bought CA$102k worth of stock

Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia

President recently bought CA$82k worth of stock

Executive Chairman recently bought CA$105k worth of stock

Executive Chairman recently bought CA$95k worth of stock

Third quarter 2021 earnings released: CA$0.07 loss per share (vs CA$0.14 profit in 3Q 2020)

High number of new directors

High number of new directors

Executive Chairman recently bought CA$105k worth of stock

CEO & Director recently bought CA$202k worth of stock

Consensus EPS estimates increase to CA$0.28

Second quarter 2021 earnings released: EPS CA$0.23 (vs CA$0.13 in 2Q 2020)

CEO & Director recently bought CA$94k worth of stock

CEO & Director recently bought CA$189k worth of stock

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

Knight Therapeutics Announces Closing of Previously Announce Acquisition and Exclusive License to Exelon® in Canada and Latin America

Consensus forecasts updated

First quarter 2021 earnings released: EPS CA$0.028 (vs CA$0.013 loss in 1Q 2020)

Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why